Solta Medical Inc (NASDAQ: SLTM) upgraded to Outperform with price target $3.75 by Morgan Keegan
Morgan Keegan upgraded Solta Medical Inc (NASDAQ: SLTM) to Outperform with price target
$3.75. Previously, Morgan Keegan rated Solta Medical Inc (NASDAQ: SLTM) to Mkt Perform with price target $3.50 on 12/14/2011, when the stock price was valued at $2.74.
Solta Medical Inc
., formerly Thermage, Inc. is engaged in designing, developing, manufacturing and marketing energy-based medical device systems for aesthetic applications. These systems are marketed under the brand names Fraxel and Thermage and are Food & Drug Administration (FDA) cleared for dermatological procedures in the applications, which include: Skin Tightening, the Thermage NXT system offers non-invasive treatment options for skin tightening and contouring, body shaping, and improvement in the appearance of cellulite; Skin Rejuvenation, the Fraxel re:fine and Fraxel re:store systems offer treatments for skin conditions such as fine lines and pigmentation.
Since Morgan Keegan
's founding 38 years ago, quality investment research has been a hallmark of the firm. Over the years, we have built our reputation by focusing on companies that have gone unnoticed by Wall Street. Today, our staff of senior equity analysts tracks more than 250 companies concentrated in ten industry sectors